This is the program for the 2010 Joint Statistical Meetings in Vancouver, British Columbia.

Activity Details

130 Mon, 8/2/2010, 8:30 AM - 10:20 AM CC-204 (West)
Interim Analyses and Assessments of Futility — Contributed Papers
Biopharmaceutical Section
Chair(s): Shanti Gomatam, FDA/CDRH
8:35 AM Futility Assessment Utilizing Conditional Power in a Phase III Clinical Trial — Yan Sun, Amgen Inc.
8:50 AM Sample Size and Power Considerations for Futility Trial Design: Buying Power vs. Spending Beta — Thomas Dobbins, Merck & Co., Inc.
9:05 AM Optimization of Error Spending Approach in Clinical Trials — Michael Baron, The University of Texas at Dallas ; Yi Zhong, The University of Texas at Dallas
9:20 AM Conditional Power and Predictive Power Approaches to Interim Monitoring in Equivalence Trials — Xiaojiang Zhan, Merck & Co., Inc.
9:35 AM Optimal Two-Stage Phase II Design Utilizing Partial Information for Long-Term Endpoints — Bo Huang, Pfizer Inc. ; Enayet Talukder, Pfizer Inc. ; Neal Thomas, Pfizer Inc.
9:50 AM Should the Conditional Type I Error Be Controlled? — Tie-Hua Ng, FDA
10:05 AM Two-Stage Designs with Additional Futility Tests for Phase II Clinical Trials with Heterogeneous Patient Populations — Myron N. Chang, University of Florida ; Sin-Ho Jung, Duke University



2010 JSM Online Program Home

For information, contact jsm@amstat.org or phone (888) 231-3473.

If you have questions about the Continuing Education program, please contact the Education Department.